

Central PA Facts

- Central PA chapter covers 24 territories from the New York and Maryland borders and stretches across the state from Altoona to Reading
- In FY2011, \$900,000 was raised by our chapter
- **October 23, 2011:** Walk to Cure Diabetes at Hersheypark. Hosted over 1700 walkers and raised over \$225,000
- **April 14, 2012:** Annual Gala at the Hershey Lodge
- **May 19, 2012:** JDRF Walk to Cure Diabetes in State College - Medler Field @ Lubrano Park
- **May 20, 2012:** JDRF Walk to Cure Diabetes in Lancaster - Lancaster Campus of HACC
- **June 28, 2012:** JDRF Golf Classic, Hershey Country Club
- Central PA chapter blog: <http://www.type1connect.org/>
- Serve as a resource to families and individuals living with type 1 diabetes:
 - Providing a “Bag of Hope” to newly diagnosed children
 - Events for adults with type 1
 - Support groups, mentoring and information about living with type 1
 - Awareness Presentations to the local community

JDRF Central PA Chapter

717 Market Street
Suite 108
Lemoyne, PA 17043

Phone: (717) 901-6489
Fax: (717) 901-6573

Executive Director: Susan Harral
Email: sharral@jdrf.org

Development Coordinator: Kelly Jackson
Email: kjackson@jdrf.org

Development Assistant: Lauren McPherson
Email: lmcperson@jdrf.org



JDRF is the leading global organization focused on type 1 diabetes (T1D) research. Driven by passionate, grassroots volunteers connected to children, adolescents, and adults with this disease, JDRF is the largest charitable supporter of T1D research.

The goal of JDRF is to improve the lives of every person affected by T1D by accelerating progress on the most promising opportunities for curing, better treating, and preventing T1D.

JDRF collaborates with a wide spectrum of partners who share this goal. Past JDRF research efforts have helped to significantly improve the care of people with this disease, and have expanded the critical scientific understanding of T1D.

JDRF will not rest until T1D is fully conquered.

What can \$1 million support?

- Our goal is to improve the lives of every person affected by T1D by accelerating progress on the most promising opportunities for curing, better treating, and preventing T1D
- Since its founding in 1970, JDRF has awarded more than \$1.5 billion to T1D research
- More than 80 percent of JDRF's expenditures directly support research and research-related education
- JDRF research focuses on:
 - Stopping or slowing its progression in people who are newly diagnosed
 - Reversing T1D, and preventing or reversing its complications, in those who have lived with the disease for years
 - Preventing T1D in people at risk and in future generations
 - Improving treatment and provide better tools to achieve tight glucose control for people at all stages of the disease
- In FY2010, JDRF funded research projects in 19 countries, including more than 40 human clinical trials.
- The JDRF artificial pancreas clinical study coordinating center for 1 year
 - Center is the data hub for the clinical studies being conducted to demonstrate the effectiveness and safety of the artificial pancreas program studies. An artificial pancreas will transform the lives of people living with T1D.
- Clinical studies like the JDRF continuous glucose monitoring study by providing support for one of the ten centers that enrolled patients towards the study goal of 450 patients.
- Genotyping of 20,000 patients with T1D
 - Understanding the genetic maps of people with T1D enables many avenues of research that could lead to cures, better treatments and ways to prevent T1D in future generations.
- Beta cell regeneration research for up to 3-4 years.
 - Both genotyping & beta cell regeneration labs recently reported groundbreaking results on new pathways for triggering beta cells to replicate more rapidly. Ultimately, beta cell regeneration could be a key component for a T1D cure using novel therapies that allow patients to replace their lost beta cell function.
- Lab research to test the effectiveness of a nanoparticle vaccine to prevent T1D or halt the misguided immune system attack on beta cells once detected.
 - Exciting new ways to control the immune system and possibly restore its normal balance in people with T1D is currently being studied
- A multi-year study of the effectiveness and safety of the combination of insulin and pramlintide in patients with T1D
 - Insulin is not the only factor controlling blood glucose in non-diabetic people. The combination of both these agents may enable people with T1D to better control their blood glucose levels and avoid dangerous high and low levels.
- 3 years of investigation into the underlying mechanisms for eye disease and kidney disease in people with T1D
 - The underlying links between T1D and complications of this disease are still not well understood. Better knowledge of the underlying causes of these complications will help reveal new approaches for therapies to prevent and treat these serious complications of T1D.